Is actin the praziquantel receptor?

Troiani, Anna Rita; Pica‐Mattoccia, Livia; Valle, Cristiana; Cioli, Donato; Mignogna, Giuseppina; Ronketti, Fiona; Todd, Matthew H.

doi:10.1016/j.ijantimicag.2007.05.004

Cited by 18 publications

(17 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Intuitively, it might be expected that PZQ would bind to its molecular targets, but a recent attempt to identify likely receptors by affinity chromatography failed [68]. An earlier report that PZQ binds adult S. mansoni worm actin [69] was thus not confirmed.…”

Section: Is Actin a Receptor?mentioning

confidence: 98%

Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis

Doenhoff

Cioli²,

Utzinger³

2008

Current Opinion in Infectious Diseases

Self Cite

713

566

View full text Add to dashboard Cite

show abstract

Section: Is Actin a Receptor?mentioning

confidence: 98%

Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis

Doenhoff

Cioli²,

Utzinger³

2008

Current Opinion in Infectious Diseases

Self Cite

713

566

View full text Add to dashboard Cite

show abstract

“…Previously many studies were carried out with attempt to investigate the mechanism of actions of praziquantel against schistosomes (Mehlhorn et al 1981(Mehlhorn et al , 1982Cunha and Noël 1997;Milhon et al 1997;Harder 2002;Cioli and Pica-Mattoccia. 2003;Ribeiro-dos-Santos et al 2006;Angelucci et al 2007;Tallima and El Ridi 2007;Troiani et al 2007;Aragon et al 2009); however, there are still plenty of mysteries that have not been disclosed. This paper reviews the researches on the effects and mechanism of praziquantel against schistosomes briefly and highlights some issues in the further studies.…”

Section: Introductionmentioning

confidence: 99%

New insight into praziquantel against various developmental stages of schistosomes

Wang

YiXin

2011

Parasitol Res

View full text Add to dashboard Cite

Praziquantel, due to high efficacy, excellent tolerability, few and transient side effects, simple administration, and competitive cost, is virtually the only drug of choice for treatment of human schistosomiasis. Treatment of schistosomiasis has shown great advances with the introduction of the drug into the therapeutic arsenal in areas that are endemic for the parasite. However, the drug presents various efficacies against different developmental stages of schistosomes, appearing an oddity intermitted mode. The present review article reviews the effects and mechanism of action of praziquantel against schistosomes briefly and suggests the research on this oddity phenomenon.

show abstract

“…Accordingly, identical patterns were obtained from the eluates, indicating that schistosome actin and myosin apparently bind non-specifically to the Affigel DOI of original article:10.1016/j.ijantimicag.2007.05.004. resin [1]. As Troiani et al [1] acknowledged, no such nonspecific binding occurs on cellulose acetate.…”

mentioning

confidence: 67%

“…Use of affinity chromatography to identify the PZQ receptor has lagged, likely owing to the inert nature of the molecule. Troiani et al [1] have recently reported their efforts to construct a PZQ column via conjugation of amino-PZQ to an Affigel support. It is of note that synthesis of amino-substituted PZQ entails some issues that should be carefully analysed.…”

mentioning

confidence: 99%